<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04242420</url>
  </required_header>
  <id_info>
    <org_study_id>BN 178/01</org_study_id>
    <nct_id>NCT04242420</nct_id>
  </id_info>
  <brief_title>Connexin Genotypes in Cystic Fibrosis</brief_title>
  <official_title>Impact of Connexin 37, Connexin 43 on Clinical Disease Phenotype in Delta F508 Homozygous Patients With Cystic Fibrosis (CF) (CF-Modifier)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital, Frankfurt</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: There is wide variety in lung disease phenotype for the delta F508 (homozygous)
      genotype. A leukocyte driven inflammation is most important for the pathogenesis of pulmonary
      disease in CF. Blood cytokines correlate negatively with pulmonary function in delta F508
      homozygous patients. Gap junction proteins might be of importance for the influx of blood
      cells into the lung and may influence the course of pulmonary inflammation.

      Aims: To assess the relationship between gap junction proteins alpha 1 (GJA1/Connexin 43) and
      alpha 4 (GJA4/connexin 37) genotypes and clinical disease phenotype.

      Methods:Patients homozygous for delta F508 get recruited from the CF centres of Bonn,
      Frankfurt and Amsterdam. Sequence analysis is performed for connexin 43 and 37. Clinical
      disease is assessed longitudinally over 3 years by pulmonary function tests (FEV1 (forced
      expiratory volume in one second), FVC (=(forced vital capacity), FEF75 % (Forced expiratory
      flow at 75% of the pulmonary volume) pred), BMI (percentiles), P. aeruginosa colonization,
      diabetes mellitus and survival to end-stage CF lung disease (death or lung transplantation).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Progressive pulmonary destruction is the major cause of morbidity and mortality in human
      subjects with cystic fibrosis. Many studies could not find an association between delta F 508
      and severity of pulmonary disease . The most important factor in CF lung disease is an
      inflammation driven by leukocytes and cytokines. The investigators have provided evidence in
      former studies that cytokines (Interleukin-8 (IL-8), tumour necrosis factor (TNF) alpha,
      Lipopolysaccahride binding protein (LBP), transforming growth factor (TGF) ß)measured in
      blood correlate negatively with lung function in delta 508 homozygous patients.

      The question arises, what other factors influence recruitment of proinflammatory leukocytes
      from blood capillaries into the lung .

      Connexins are a family of transmembrane proteins, which oligomerize into hexameric structures
      to form a hemichannel (connexon) and ultimately pair with a partner hemichannel in an
      adjacent cell to form gap junction intercellular communication channels (GJIC) . There is
      evidence of expression of connexin 37 (=gap junction protein A4 (GJA4)) on macrophages in
      humans. Moreover there is evidence of expression of connexin 37 on vascular endothelia in
      humans . Connexin 37 is expressed on human neutrophils . Pulmonary disease in CF is dominated
      by a leukocyte driven inflammation. GAP junction proteins might be of importance for the
      influx of blood cells into the lung. In this regard, the hypothesis was that Cx37 or Cx43
      genotypes have an impact on clinical disease phenotype in CF patients homozygous for delta
      F508.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2002</start_date>
  <completion_date type="Anticipated">December 31, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Evaluation of clinical parameters by genotype</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival to end stage lung disease</measure>
    <time_frame>through study completion, on average 27 years</time_frame>
    <description>End stage lung disease: Death or lung transplantation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung function parameter: FEV1</measure>
    <time_frame>3 years</time_frame>
    <description>Best FEV1 value in % predicted of the year according to German registry according to Global lung initiative (GLI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung function parameters: FVC</measure>
    <time_frame>3 years</time_frame>
    <description>Best FVC value in % predicted of the year according to German registry according to Global lung initiative (GLI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Lung function parameters: FEF75</measure>
    <time_frame>3 years</time_frame>
    <description>Best FEF75 value in % predicted of the year according to German registry according to Global lung initiative (GLI)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Interleukin-8 in blood</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>single spot value (cross-sectional)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Interleukin-8 in sputum</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>single spot value (cross-sectional)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>White blood cell count</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>Leukocytes (single spot value (cross-sectional))</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory markers in sputum</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>Leukocyte count in sputum (single spot value (cross-sectional))</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Colonisation with Pseudomonas aeruginosa</measure>
    <time_frame>3 years</time_frame>
    <description>Never, Intermittent or chronic according to Leeds criteria</description>
  </other_outcome>
  <other_outcome>
    <measure>CF related diabetes mellitus</measure>
    <time_frame>through study completion, an average of 3 year</time_frame>
    <description>Assessment via patient charts/ registry</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Cystic Fibrosis</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Connexin genotype</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Genotyping</intervention_name>
    <description>Genotyping for single nucleotide polymorphisms for Connexin 37&amp;43</description>
    <arm_group_label>Connexin genotype</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Lung function</intervention_name>
    <description>Spirometry</description>
    <arm_group_label>Connexin genotype</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Microbiology</intervention_name>
    <description>Bacterial culture from Sputum or swab</description>
    <arm_group_label>Connexin genotype</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Blood sample</intervention_name>
    <description>Interleukin-8 assay (via chemiluminescence) blood cell count</description>
    <arm_group_label>Connexin genotype</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Induced Sputum</intervention_name>
    <description>Interleukin-8 assay (via chemiluminescence) blood cell count</description>
    <arm_group_label>Connexin genotype</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Homozygosity for delta F 508

        Exclusion Criteria:

        treatment with systemic steroids 14 days preceding this trial, participation in another
        study within the past 30 days, treatment with Orkambi or status after lung transplantation
        (for assessment of all parameters except survival).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabina Schmitt-Grohe, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Bonn</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabina Schmitt-Grohe, MD</last_name>
    <phone>004915254568942</phone>
    <email>s.schmitt-grohe@ukbonn.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessia</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christina Smaczny, MD</last_name>
      <phone>0049-69-6301</phone>
      <phone_ext>4232</phone_ext>
      <email>smaczny@em.uni-frankfurt.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhine-Westphalia</state>
        <zip>53113</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabina Schmitt-Grohe, MD</last_name>
      <phone>004915254568942</phone>
      <email>s.schmitt-grohe@ukbonn.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Neerinx-vanStuvyenberg, PhD</last_name>
      <email>a.vanstuyvenbergneerincx@amc.uva.nl</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <reference>
    <citation>Cystic Fibrosis Genotype-Phenotype Consortium. Correlation between genotype and phenotype in patients with cystic fibrosis. N Engl J Med. 1993 Oct 28;329(18):1308-13.</citation>
    <PMID>8166795</PMID>
  </reference>
  <reference>
    <citation>McKone EF, Goss CH, Aitken ML. CFTR genotype as a predictor of prognosis in cystic fibrosis. Chest. 2006 Nov;130(5):1441-7.</citation>
    <PMID>17099022</PMID>
  </reference>
  <reference>
    <citation>Schmitt-Grohé S, Naujoks C, Bargon J, Wagner TO, Schubert R, Hippe V, Zielen S. Interleukin-8 in whole blood and clinical status in cystic fibrosis. Cytokine. 2005 Jan 7;29(1):18-23.</citation>
    <PMID>15579374</PMID>
  </reference>
  <reference>
    <citation>Schmitt-Grohé S, Hippe V, Igel M, von Bergmann K, Posselt HG, Krahl A, Smaczny C, Wagner TO, Nikolazik W, Schubert R, Lentze MJ, Zielen S. Lipopolysaccharide binding protein, cytokine production in whole blood, and lipoproteins in cystic fibrosis. Pediatr Res. 2005 Nov;58(5):903-7. Epub 2005 Sep 23.</citation>
    <PMID>16183806</PMID>
  </reference>
  <reference>
    <citation>Schmitt-Grohé S, Stüber F, Book M, Bargon J, Wagner TO, Naujoks C, Schubert R, Lentze MJ, Zielen S. TNF-alpha promoter polymorphism in relation to TNF-alpha production and clinical status in cystic fibrosis. Lung. 2006 Mar-Apr;184(2):99-104.</citation>
    <PMID>16622779</PMID>
  </reference>
  <reference>
    <citation>Eickmeier O, Boom Lv, Schreiner F, Lentze MJ, NGampolo D, Schubert R, Zielen S, Schmitt-Grohé S. Transforming growth factor β1 genotypes in relation to TGFβ1, interleukin-8, and tumor necrosis factor alpha in induced sputum and blood in cystic fibrosis. Mediators Inflamm. 2013;2013:913135. doi: 10.1155/2013/913135. Epub 2013 Aug 26.</citation>
    <PMID>24062613</PMID>
  </reference>
  <reference>
    <citation>Dempsie Y, Martin P, Upton PD. Connexin-mediated regulation of the pulmonary vasculature. Biochem Soc Trans. 2015 Jun;43(3):524-9. doi: 10.1042/BST20150030. Review.</citation>
    <PMID>26009202</PMID>
  </reference>
  <reference>
    <citation>Chanson M, Derouette JP, Roth I, Foglia B, Scerri I, Dudez T, Kwak BR. Gap junctional communication in tissue inflammation and repair. Biochim Biophys Acta. 2005 Jun 10;1711(2):197-207. Epub 2004 Oct 30. Review.</citation>
    <PMID>15955304</PMID>
  </reference>
  <reference>
    <citation>Kwak BR, Mulhaupt F, Veillard N, Gros DB, Mach F. Altered pattern of vascular connexin expression in atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2002 Feb 1;22(2):225-30.</citation>
    <PMID>11834520</PMID>
  </reference>
  <reference>
    <citation>Zahler S, Hoffmann A, Gloe T, Pohl U. Gap-junctional coupling between neutrophils and endothelial cells: a novel modulator of transendothelial migration. J Leukoc Biol. 2003 Jan;73(1):118-26.</citation>
    <PMID>12525569</PMID>
  </reference>
  <reference>
    <citation>Sáez PJ, Shoji KF, Aguirre A, Sáez JC. Regulation of hemichannels and gap junction channels by cytokines in antigen-presenting cells. Mediators Inflamm. 2014;2014:742734. doi: 10.1155/2014/742734. Epub 2014 Sep 9. Review.</citation>
    <PMID>25301274</PMID>
  </reference>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>December 20, 2019</study_first_submitted>
  <study_first_submitted_qc>January 24, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 27, 2020</study_first_posted>
  <last_update_submitted>January 24, 2020</last_update_submitted>
  <last_update_submitted_qc>January 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Childrens' Hospital (Zentrum für Kinderheilkunde des Universitätsklinikum Bonn)</investigator_affiliation>
    <investigator_full_name>Sabina Schmitt-Grohe</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <keyword>connexin 37+43</keyword>
  <keyword>Lung function</keyword>
  <keyword>Interleukin 8</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

